What do systematic reviews say?

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 129 participants
  Very low

Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Adjuvant chemotherapy vs no chemotherapy

The review found no eligible studies for this question.

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Radioembolisation vs chemoembolisation

• Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Very low

Radioembolisation plus sorafenib vs sorafenib monotherapy

The review found no eligible studies for this question.

• Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Radioembolisation vs sorafenib monotherapy

• Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 360 participants
  Very low

TACE followed by 3‐DCRT vs chemoembolisation

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 66 participants
  Very low

Gemcitabine plus cisplatin vs S‐1 plus cisplatin

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus S‐1 vs S‐1

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus oxaliplatin vs best supportive care

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus vandetanib vs vandetanib

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone

The review found no eligible studies for this question.

• External beam radiotherapy for unresectable hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Percutaneous ethanol injection vs radiofrequency ablation

The review found no eligible studies for this question.

• Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser ablation vs radiofrequency ablation

The review found no eligible studies for this question.

• Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found